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ABSTRACT 
The risk of recurrence of stage II colorectal cancer is difficult to predict. A part of 
recurrences take place among patients without any of the known high-risk factors 
such as lymphovascular invasion or preoperative obstruction. In addition, 
microsatellite instability status and tumour budding have been included to risk 
stratification of colorectal cancer patients. The aim of this study is to find new 
biomarkers and their combinations, which could more efficiently identify high risk 
stage II colorectal cancer patients. For this purpose, a cohort of 232 stage II 
colorectal cancer patients treated at Turku University Hospital has been collected 
and a tissue microarray has been constructed from their paraffin-embedded tumour 
material. 
Ezrin is a cytoskeleton-associated protein that participates in cellular signaling, 
cell survival, proliferation and migration. High protein expression of ezrin in 
cancer cells has been linked to poor outcome in many cancer types. The diminished 
protein expression of transcription factor CDX2 has been associated with inferior 
outcome in stage II and III colorectal cancer. The association of high tumour 
budding with poor outcome in colorectal cancer has been well documented, but the 
molecular biological mechanisms behind this are poorly known. There is evidence 
that tumour budding is associated with epithelial-mesenchymal transition (EMT) 
but the exact molecular biological mechanism of this has not been properly studied. 
In this study, the protein expression of ezrin, CDX2 and EMT markers integrin 4 
beta, E-cadherin and ZO-1 have been studied in relation to clinicopathological 
variables and survival. 
The main results of the studies showed high ezrin protein expression and 
CDX2 loss in patients with microsatellite stable tumours to be independent risk 
factors of poor disease-specific survival in stage II colorectal cancer. High 
expression of EMT-marker integrin 4 beta in tumour buds analysed with digital 
image analysis correlates with visual tumor budding analysis, and it proved to be 
an independent risk factors of poor disease-specific survival. In conclusion, high 
ezrin protein expression, CDX2 loss and EMT-marker integrin 4 beta are new 
promising biomarkers in risk stratification of stage II colorectal cancer patients. 
KEYWORDS: colorectal cancer, biomarker, survival, tissue microarray   
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TIIVISTELMÄ 
Levinneisyysasteen II paksu- ja peräsuolisyövän uusiutumisriskiä on vaikea 
ennustaa. Osa taudin uusiutumisista tulee potilaille, joilla ei ole yhtään tällä 
hetkellä tunnetuista korkean uusiutumisriskin tekijöistä, kuten suoni-invaasio tai 
kasvaimen ennen leikkausta aiheuttama tukkeutuminen. Näihin riskitekijöihin on 
lisätty myös mikrosatellitti-instabiliteetti ja syövän silmuileva kasvutapa. Tämän 
tutkimuksen tavoitteena on löytää uusia biomarkkereita ja niiden yhdistelmiä, jotka 
voisivat aiempaa tehokkaammin tunnistaa tämän levinneisyysasteen korkean 
uusiutumisriskin potilaita. Tätä tarkoitusta varten on kerätty Turun yliopistollisessa 
keskussairaalassa hoidettujen 232 levinneisyysasteen II paksu- ja peräsuoli-
syöpäpotilaiden aineisto, joista on kerätty kliinispatologiset tiedot ja heidän 
kasvainmateriaalistaan on valmistettu monikudosblokit eli kudosmikrosiru.  
Ezrin on solun tukirangan proteiini, joka osallistuu mm. solusignalointiin, 
jakautumiseen ja liikkumiseen. Korkea ezrin-proteiinin ilmeneminen syöpäsoluissa 
on liitetty huonoon ennusteeseen useissa syöpätyypeissä. CDX2-transkriptiotekijän 
vähentynyt proteiinitason ilmeneminen on liitetty huonoon ennusteeseen levin-
neisyysasteen II ja III paksu- ja peräsuolisyövässä. Syövän silmuilevan kasvutavan 
on useissa tutkimuksissa todettu liittyvän huonoon ennusteeseen paksu- ja 
peräsuolisyövässä, mutta tämän taustalla olevia mekanismeja tunnetaan huonosti. 
Tässä tutkimuksessa ezrin- ja CDX2-proteiinien ja epiteeli-mesenkyymaaliseen 
transitioon liittyvien integrin 4 beta, E-cadherin ja ZO-1 proteiinien proteiinitason 
ilmenemistä on tutkittu potilaiden syöpäkudosta sisältävien monikudosblokkien 
avulla. Näiden proteiinien ilmenemisprofiileita on verrattu potilaiden 
kliinispatologisiin tietoihin ja eloonjäämiseen. 
Työn päätulokset osoittivat, että korkea ezrin-proteiinin ilmeneminen ja heikko 
tai puuttuva CDX2 proteiinin ilmeneminen ovat huonon ennusteen tekijöitä niillä 
potilailla, joiden kasvaimet ovat ns. mikrosatelliitti-stabiileja. Edelleen epiteeli-
mesenkymaaliseen transitioon assosioituvan integrin 4 beta -proteiinin korkea 
ilmeneminen syövässä ns. syöpäsilmujen alueella on huonon ennusteen tekijä. 
Yhteenvetona voidaan todeta, että korkea ezrin-proteiinin ilmeneminen, CDX-2-
proteiinin ilmenemisen vaimeneminen ja integrin 4 beta ovat uusia lupaavia levin-
neisyysasteen II paksu- ja peräsuolisyövän biomarkkereita. 
AVAINSANAT: paksu- ja peräsuolisyöpä, biomarkkeri, eloonjäämisennuste, 
kudosmikrosiru   
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1 Introduction 
In both sexes combined, colorectal cancer (CRC) is the third most commonly 
diagnosed cancer worldwide (Ferlay et al. 2018; Kuipers et al. 2015), and it ranks 
second in terms of mortality (Bray et al. 2018). 
CRC is a disease that reflects socio-economic development (Bray et al. 2018). 
The incidence rates have continued to increase in economically transitioning 
countries, along with the consumption of high fat diet, physical inactivity and 
smoking (Mehta et al. 2017). CRC mortality rates have gradually decreased in 
highly developed countries with improvements in survival due to using modern 
surgical and oncological treatments and stage assessment (Bray et al. 2018).  
The 5-year survival ranges from over 90 % for stage I, 82–87 % for stage II, 60 
% for stage III and under 10% for stage IV CRC (White et al. 2018). In stage I–II 
disease, colonic resection is the optimal treatment, whereas some stage I cases can 
be treated with local polypectomy. In stage III disease and in high risk stage II 
disease, adjuvant chemotherapy is recommended after a colonic resection to reduce 
the risk of recurrence. (van de Velde et al. 2014). The treatment options for stage 
IV disease have evolved lately along with the possibility for biologic treatments 
with the anti-epidermal growth factor receptor (EGFR), the anti-vascular 
endothelial growth factor (VEGF) receptor targeted therapies, and the advanced 
surgical procedures for liver metastases (Lang et al. 2018). Stage II CRC patients 
are still a problematic group in selecting the optimal treatment, because the 
outcome of these patients is very variable (Amri et al. 2016). Relapses may occur 
in this group of patients despite the absence of any of the currently acknowledged 
risk factors: T4 disease, grade 3, preoperative obstruction, perforation, 
lymphovascular or perineural invasion, and less than 12 examined lymph nodes 
(Dotan & Cohen 2011). Consequently, these currently known risk factors lack 
sufficient accuracy in defining the recurrence risk in stage II CRC (Tsikitis et al. 
2014). There should be more efficient tools in the identification of stage II CRC 
patients at risk of relapse, and new biomarkers are still needed. 
Several studies have demonstrated that patients with microsatellite instability 
(MSI) in their tumours have  better outcome in relation to time to recurrence 
(TTR), relapse free survival (RFS) and overall survival (OS) as compared to 
Khadija Slik 
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patients with microsatellite stable (MSS) tumours, especially among stage II CRC 
patients (Amri et al. 2016; Merok et al. 2013). Tumour budding (TB) is defined as 
single tumour cells or cell clusters of up to four cells at the invasive margin of 
CRCs (Lugli et al. 2017). The evaluation of TB has been used as a tool to identify 
high risk stage II CRC patients, since high TB has been regarded as a marker of 
poor outcome in this group of CRC patients (Wang et al. 2009). There is evidence 
that TB is associated with KRAS mutation (G12D), BRAF-mutations, mismatch 
repair (MMR) proficient disease and lymphovascular invasion (Prall et al. 2007; 
Zlobec et al. 2012; Jang et al. 2017; Mitrovic et al. 2012). In addition, several 
studies suggest a connection between TB and epithelial-to-mesenchymal transition 
(EMT) (De Smedt et al. 2017), which may reveal new tools for patient 
prognostication. CDX2 is a marker which has been used in clinical pathology for a 
long time to identify the cancers of intestinal origin (Groisman et al. 2005). For 
some years ago it was found that CDX2–negative CRCs were associated with a 
lower rate of disease-free survival (DFS) than those that had preserved CDX2 
protein expression (Dalerba et al. 2016). In addition, a strong association between 
negative CDX2 protein expression has been shown with MSI-high (MSI-H) 
phenotype as well as with BRAF mutation (Olssen et al. 2016; Zlobec et al. 2010; 
Landau et al. 2014). However, there are not many studies of the prognostic role of 
CDX2 loss specifically in stage II CRC. 
In the current study, the combination of these recently acknowledged 
biomarkers have been studied in relation to survival with a cohort of stage II CRC 
patients treated at Turku University Hospital between the years 2005–2012.  
  13 
2 Review of the Literature 
2.1 Epidemiology of colorectal cancer  
Globally, CRC is the third most commonly diagnosed malignancy in men and the 
second most commonly diagnosed malignancy in women (Ferlay et al. 2010). Its 
incidence is higher in many countries among men than among women (Torre et al. 
2012). Globally, CRC incidence is variable with about 55% of cases occurring in 
developed countries, the highest incidence rates in Northern America, Europe, New 
Zealand and Australia. The areas with low incidence rates are in Africa, South – 
Central Asia and Central America (Favorti et al. 2016). 
CRC affects mainly western people, but its incidence has started to rise in 
many countries with traditionally lower incidence rates as well (Marley & Nan 
2016). European Union statistics of the year 2018 showed that the CRC accounts as 
a whole for the second highest number of cancer deaths, a total number of 177400, 
with rates of 15.8/100 000 among men and 9.2/100 000 among women. It ranks the 
second cause of cancer related deaths in men and the third cause of cancer related 
deaths in women (Ferlay et al. 2018). 
It is estimated that CRC continues to increase worldwide because of the 
constant aging and growth of population as well as the spread of the western 
lifestyle in economically developing countries (Favoriti et al. 2016). Incidence, 
mortality, and survival rates vary by race and ethnicity (Jackson-Thomson et al. 
2006). There are large differences in CRC survival rates globally according to 
stage at the time of diagnosis, which may be explained by the differences in the 
availability of diagnostic methods and the quality of treatments (Boyle & Langman 
2000).  
2.2 Etiology of colorectal cancer 
CRC is a multi-factorial disease with a complicated environmental and genetic 
etiology (Aran et al. 2016). From its genomic properties, CRC cannot be regarded 
as a single disease but a variable group of malignant neoplasms of colonic origin 
(Testa et al. 2018). Most of the cases are sporadic and occur at 50 years of age or 
older. Some cases are familial or associated with inherited syndromes and present 
Khadija Slik 
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with younger age (Emre et al. 2018). Altogether, 20–30% of CRCs have a familial 
trait and 5% of these tumours arise through Mendelian inheritance pattern (Testa et 
al. 2018). 
2.2.1 Adenomatous or serrated polyps – precursors of 
colorectal cancer 
Many CRC patients have a premalignant lesion before the development of 
carcinoma, most commonly an adenomatous polyp or less frequently a serrated 
polyp (SP) (Testa et al. 2018). The conventional adenomas and SPs are believed to 
arise from distinct pathways (He et al. 2018). These include adenoma-carcinoma 
pathway and the serrated pathway, which have their own genetic characteristics 
(Testa et al. 2018). 
2.2.2 Chromosomal instability (CIN) and microsatellite 
instability (MSI) pathways 
There are two main pathways involved in the development of CRC. These include 
CIN and MSI pathways with a progression to advanced adenomas and cancers. 
CIN is typical of adenoma-carcinoma-pathway, where adenomas develop through 
inactivation of the tumour suppressor gene adenomatous polyposis coli (APC) 
followed by the progression of the dysplastic adenoma gradually to 
adenocarcinoma (Shiller & Boostrom 2015). MSI pathway with a deficient MMR 
gene is typical of serrated pathway. This pathway is proposed to be the origin of 
hyperplastic polyps (HPs), which are hypothesized to transform to sessile serrated 
lesion (SSL) or traditional serrated adenoma (TSA) accompanied with progressive 
dysplastic changes and finally the development of invasive carcinoma (Bettington 
et al. 2013). In sporadic cancers with MSI, the MMR gene defect is linked with the 
epigenetic silencing of the MLH1 gene as a result of hypermethylation of the 
promoter region, which leads to accumulated mutations and inability to repair them 
leading ultimately to the development of cancer (Yearsley et al. 2006). These 
cancers typically also have CPG island hypermethylation and BRAF mutation 
(Bettington et al. 2013). Alternatively, the MMR gene deficiency can originate 
from germline mutation in one of the following genes: MLH1, PMS2, MSH2 or 
MSH6, which is the case in Lynch syndrome (Pochapin 2018). 
2.2.3 Hereditary colorectal cancer 
Also known by the name of hereditary non-polyposis CRC, Lynch syndrome (LS) 
is a genetic cancer syndrome with an autosomal dominant trait. It is a disease of 
Review of the Literature 
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familial cancer aggregation associated with deficient MMR and an increased risk 
of CRC (Buchanan et al. 2010). Patients with LS have a MSI-H carcinoma because 
of germ line mutation in one of MMR genes: MLH1, PMS2, MSH2 or MSH6. 
(Yearsley et al. 2006), and the incidence of this syndrome is about 3 % (Win et al. 
2017). It occurs at a younger age than sporadic CRC (Sinicrope 2018). LS also 
predisposes to several other cancers including endometrial adenocarcinoma, 
urothelial carcinoma, pancreatic cancer and gastric cancer (Latham et al. 2019). LS 
may show poor differentiation including mucinous features or a medullary growth 
pattern, right-side predominance, and abundance of lymphocytic infiltration as a 
reaction to neoantigens developed due to numerous mutations (Sinicrope 2018).  
Familial adenomatous polyposis (FAP) is a familial disease associated with 
inherited mutations of the APC gene. It presents as a rather rare familial polyposis 
syndrome with hundreds or thousands of adenomas in colorectum. It inevitably 
leads to development of CRC at the age of 40 years at the latest. Attenuated 
familial adenomatous polyposis (AFAP), a milder form of FAP is characterized by 
fewer numbers adenomas and later onset of CRC than in FAP (Kantor et al. 2017). 
Juvenile polyposis and Peutz-Jeghers syndrome are rare diseases inherited as an 
autosomal dominant trait and associate with a high risk to develop CRC (Rosenthal 
et al. 2018). Furthermore, there are syndromes with increased risk of CRC 
associated with SPs (Buchanan et al. 2010). 
2.2.4 Colorectal cancer related with inflammatory bowel 
disease 
Crohn’s disease and ulcerative colitis belong to inflammatory bowel diseases (IBDs). 
They are associated with an increased risk for CRC (Garg & Loftus 2016). This risk 
is related to the extent and duration of the disease (Huang & Merchea 2017).  
Development of cancer in the colon with IBD is attributed to chronic 
inflammation and immune dysregulation. Chronic inflammation will induce 
malignant transformation of the colonic mucosa (Garg & Loftus 2016) through the 
generation of adverse factors causing inactivation of tumour-suppressor genes (e.g., 
P53 mutation), and activation of oncogenes (e.g., KRAS mutation). In addition, 
chronic inflammation activates the spread of inflammatory mediators including 
IL6, IL1b and TNFa. They activate NF-kB, which results in neoplastic 
transformation of the intestinal epithelium (Meng et al. 2017). 
2.2.5 Colorectal cancer and environmental factors 
Lifestyle and environmental factors play an important role in CRC. There are 
several studies which have shown that food with an abundance of meat and animal 
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fat can function as carcinogenesis promoters in CRC, while a diet rich in fish meat, 
fiber, vitamin D and calcium can protect from CRC (Marley et al. 2016). Some of 
these environmental factors have been observed to associate differently with SPs 
and conventional adenomas (He et al. 2018). A diet high in fat favors the increase 
of sulfate-reducing bacteria, Desulfovibrio vulgaris among others. These bacteria 
participate in the transformation of primary bile acids to tumourigenic metabolites, 
like deoxycolic acid, for instance. (Meng et al. 2018).  
There is evidence that both alcohol and smoking are related with increased risk 
of CRC. Alcohol intake augments the probability of premalignant polyps and CRC 
in a dose-dependent manner (Fagunwa et al. 2017). Ethanol has been noticed to 
cause damage to intestinal epithelial cells by inducing DNA breaks. The main 
degradation product of ethanol, acetaldehyde, can cause degradation of folate, 
which may predispose to chromosomal damage (Fagunwa et al. 2017). The 
association between smoking and increased risk of CRC is related to carcinogens in 
tobacco, including polycyclic aromatic hydrocarbons (Durko et al. 2014). In 
addition, the cytochrome P450 system may potent the effect of these carcinogens 
and thus increase the probability of mutations in colonic epithelial cells, and the 
probability of key mutations for colorectal carcinogenesis, like those in KRAS and 
BRAF genes (Leufkens et al. 2011). Smoking has been reported to be linked more 
strongly with serrated pathway carcinogenesis than adenoma – carcinoma pathway 
(He et al. 2018).  
The significance of infectious agents as carcinogenesis promoting factors ranks 
third after dietary factors and smoking (De Flora & La Maestra 2015). According 
to one study about in 15 % of newly diagnosed cancers worldwide infectious 
agents attribute to neoplastic transformation, such as hepatitis B virus infection 
(Plummer et al. 2016). In addition to directly carcinogenic infectious agents, 
microbial dysbiosis increases the susceptibility to cancer. This takes place through 
inducing inflammation and dysregulation of immunity, which can cause genetic 
instability and interference of pharmacodynamics regarding anticancer agents 
(Meng et al. 2018). 
2.3 Diagnostics of colorectal cancer 
Since among some of the patients the diagnosis is delayed which is associated with 
poor outcome, (Zarcos-Pedrinaci et al. 2018), screening may reduce these cases 
and offer an opportunity to detect and treat the disease at an early stage. (Chen et 
al. 2019). Progression of CRC from adenomatous polyps to invasive cancer takes 
many years (Brenner et al. 2013). Screening for CRC has been proved to be 
effective in reducing CRC incidence and mortality and is recommended from the 
age of 50 years and older. Fecal blood tests and endoscopy are mostly used for this 
Review of the Literature 
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purpose (Sur et al. 2019). Clinical symptoms, especially a change in bowel habits 
and blood in the stool, should lead to suspicion of CRC (John et al. 2010). After 
anamnesis and clinical examination including digital rectal palpation, endoscopy 
should be made, if there is a clear suspicion of CRC. If an endoscopy is not 
possible, imaging tests should be done (Lopes et al. 2019). Double-contrast barium 
enema (DCBE), studying the colon using X-rays, was one of the most frequent past 
techniques, but it is currently rarely used partly because of high radiation burden 
(Neri et al. 2010). Computed tomographic colonoscopy (CT-Co) is a technique, 
where the colon is inflated with air, and the distended colon is studied with the aid 
of computed tomography. It is a safe procedure, which can detect extracolonic 
pathologic lesions in non- complaining patients (Mazeh et al. 2013). It has 66.8% 
of sensitivity and 80.3% of specificity diagnostic rates (Hadjipetrou et al. 2017). 
When the diagnosis of CRC has been confirmed, the whole body computed 
tomography (CT) is performed to exclude distant metastasis (Labianca et al. 2013). 
Pelvic magnetic resonance imaging (MRI) helps to determine the type of operation 
technique in rectal cancer cases (Glynne-Jones et al. 2017). Preoperative serum 
marker carcinoembryonal antigen (CEA) is determined as a baseline value for the 
follow-up of CRC patients (Labianca et al. 2013). 
2.4 Histological classification and staging 
Approximately 95% of CRCs are adenocarcinomas (Bosman et al. 2010). Of the 
CRCs that are adenocarcinomas, most are conventional adenocarcinomas with a 
variably amount of glandular formation. There are histological variants of 
colorectal adenocarcinoma. The most common of them include mucinous 
adenocarcinoma which is characterized by an abundant extracellular mucin 
production of > 50 % of tumour volume and signet ring cell carcinoma which is 
characterized by cancer cells with signet ring cells of > 50 % of tumour volume. 
Their prognosis is somewhat worse than conventional adenocarcinoma, but 
tumours of these histologic types with MSI-H behave as low-grade carcinomas 
(Fleming et al. 2012). Other histologic types include medullary carcinoma and 
serrated carcinoma. The former is characterized by a favorable prognosis in spite of 
poorly differentiated histology and often with lymphocytic infiltration (Pyo et al. 
2016). The latter is often associated with CPG island methylator phenotype (CIMP) 
and BRAF mutation with serrated histological features (Bettington et al. 2017).  
T-stage describes the extent of the tumour on/through the colonic wall (T1-T4),  
N-stage the absence/presence as well as the number of metastatic lymph nodes 
(N0-N2b) and the M-stage the presence or absence of distant metastases, as 
described in Table 1. Staging of CRC utilizes TNM8 classification currently (Table 
1). 
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Table 1.  TNM Classification of colorectal cancer, 8th edition.* 
T-Primary Tumour N-regional Lymph nodes 
Tx Primary tumour cannot be assessed Nx Regional lymph nodes cannot be 
assessed 
T0 No evidence of primary tumour N0 No regional lymph node metastasis 
Tis1 Carcinoma in situ: intraepithelial or invasion 
of lamina propria 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph 
node 
N1b Metastasis in 2-3 regional lymph 
nodes 
N1c Tumour deposit(s), i.e. satellites*, 
in the subserosa, or in non-
peritonealized pericolic or perirectal 
soft tissue without regional lymph 
node metastasis 
  N2 Metastasis in 4 or more regional lymph 
nodes 
N2a Metastasis in 4-6 regional lymph 
nodes 
N2b Metastasis in 7 or more regional 
lymph nodes 
T1 Tumour invades submucosa   
T2 Tumour invades muscularis propria   
T3 Tumour invades subserosa or into the non-
peritonealized pericolic or perirectal tissues 
  
T4 Tumour directly invades other organs or 
structures and/or perforates visceral 
peritoneum 
T4a Tumour perforates visceral peritoneum 
T4b Tumour directly invades other organs 
or structures2,3 
  
 Notes:  Notes: 
1. Tis includes cancer cells confined within the 
glandular basement membrane 
(intraepithelial) or mucosal lamina propria 
(intramucosal) with no extension through 
the muscularis mucosae into the 
submucosa 
 *Tumour deposits (satellites), i.e. 
macroscopic or microscopic nodules of 
cancer in the pericolorectal adipose 
tissue’s lymph drainage area of a 
primary carcinoma that are 
discontinuous from the primary and 
without histological evidence of residual 
lymph node or identifiable vascular or 
neural structures. If a vessel wall is 
identifiable on H&E, elastic or other 
stains, it should be classified as venous 
invasion (V1/2) or lymphatic invasion 
(L1). Similarly, if neural structures are 
identifiable, the lesion should be 
classified as perineural invasion (Pn1). 
The presence of tumour deposits does 
not change the primary tumour T 
category, but changes the node status 
(N) to pN1c if all lymph nodes are 
negative on pathological examination. 
2. Direct invasion in T4b includes invasion of 
other organs or segments of the colorectum 
by way of the serosa, as confirmed on 
microscopic examination or for tumours in a 
retroperitoneal or subperitoneal location, 
direct invasion of other organs or structure 
by virtue of extension beyond the 
muscularis propria. 
 
3. Tumour that is adherent to other organs or 
structures, macroscopically, is classified 
cT4b. However, if no tumour is present in 
the adhesion, microscopically, the 
classification should be pT1-3, depending 
on the anatomical depth of wall invasion. 
 
   M – Distant Metastasis 
   Mx Distant metastasis cannot be 
assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to one organ or 
site (eg. liver, lung, ovary, non-regional 
nodes) without peritoneal metastasis 
M1b Metastases in more than one organ 
M1c Metastasis to the peritoneum with 
or without other organ involvement. 
*According to Brierley JD, Gospodarowicz MK, Wittekind C (eds). (2017). TNM Classification of 
Malignant Tumours (Eighth Edition), UICC, John Wiley & Sons, Ltd, pp. 73–76. Reprinted with 
permission from John Wiley & Sons Limited to be used in Khadija M Slik’s thesis. 
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2.5 Treatment of colorectal cancer 
High quality surgery is the most crucial step of treatment (Lee et al. 2017). Surgical 
resection (colectomy) is the main treatment modality for patients with stage I and II 
CRC. For high risk stage II CRC patients and for those with stage III disease, 
adjuvant chemotherapy is given after surgery to decrease the risk of recurrence 
(van de Velde et al. 2014).  
Short-course preoperative radiotherapy is considered for rectal cancer patients 
with a suspicion of lymph node metastasis and long-course chemoradiotherapy for 
patients with T4 tumours or tumours with a suspicion of involved circumferential 
margin (CRM) (Glynne-Jones et al. 2017). Therapeutic modalities for stage IV 
patients include surgery, chemotherapy and radiotherapy. At the time of diagnosis, 
approximately 25 % of patients are diagnosed with liver metastases. When the 
recurrent disease is included, approximately 50 % of patients end up having a 
metastatic disease. (Cook et al. 2005). The combination of chemotherapy, targeted 
treatments with anti-EGFR and anti-VEGF monoclonal antibodies, surgery, 
interventional radiology and radiotherapy have even brought a possibility of 
curative outcome for selected stage IV CRC patients with lung or liver metastases 
(Van Cutsem et al. 2016). Finally, palliative systemic chemotherapy with or 
without bevacizumab or anti-EGFR treatment can be given to patients with 
unresectable disease, in order to improve quality of life and to prolong survival 
(Van Cutsem et al. 2016). 
2.6 Prognosis of colorectal cancer 
The 5-year survival rate of CRC in Finland is 63 % (Finnish Cancer Registry 
2016). The prognosis depends on the stage of cancer at the time of diagnosis. 
During the last decades the treatment and diagnostics of CRC have developed 
considerably with improvement of survival (Heervä et al. 2018). Patients with 
stage I CRC have excellent prognosis and their 5-year survival is more than 90 %. 
Recurrence after surgery for 5–10 % of stage I CRC patients means a worse 
outcome (Patel et al. 2014). For stage II CRC patients, the 5-year survival is  
70–80 % (Sato et al. 2011), and that for subgroup of stage III disease only 40–45 % 
(Walkers et al. 2018). Moreover, the prognosis of metastasized CRC has improved 
mostly because of active surgery as well as due to new targeted treatments with 
anti-EGFR and anti-VEGF monoclonal antibodies. Even if the average 5-year 
survival rates of stage IV is about 10 % (Siegel et al. 2012), the 5-year survival of 
selected stage IV patients with combination treatments has markedly improved 
(Chakedis & Schmidt 2018). 
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2.7 Established and provisional prognostic factors 
of stage II colorectal cancer 
The stage of CRC at the time of diagnosis is the most important prognostic factor. 
However, the heterogeneity of outcome especially among stage II CRC patients 
causes challenges in selecting optimal treatment. The presently known high risk 
factors for stage II CRC include lymphovascular invasion, involved circumferential 
margin, poor differentiation grade, perineural invasion, preoperative obstruction, 
perforation and less than 12 examined lymph nodes (Wibe et al, 2002; Dotan & 
Cohen 2011). Though, these currently known risk factors lack sufficient accuracy 
for stage II CRC patients at risk of recurrence (Tsikitis et al. 2014). During the last 
few years new biomarkers for this purpose have established their position. These 
include especially MSI-status and tumour budding (TB). 
2.7.1 MSI 
The MSI-H tumours have a defective mismatch repair system (dMMR) because of 
inactivation of one of the MMR-genes, either because of epigenetic mechanism or 
germline mutation (Nojadeh et al. 2018). The typical features of MSI-H CRCs 
include the location in proximal colon, poor differentiation grade, considerable 
lymphocytic infiltration, mucinous histological type and mutations in transforming 
growth factor beta receptor II (TGFBR II) and BRAF-genes (Hyde et al. 2010). 
About 15 % of CRC patients have been found to have MSI-H phenotype, while the 
majority of CRCs are MSS tumours (Leicher et al. 2018; Puccini et al. 2017). 
While the prognosis of patients with MSS CRC is stage and grade dependent, it has 
been observed that especially in early stages MSI-H tumours have more favorable 
prognosis than MSS tumours of the same stage (Halpern et al. 2017). Still, MSI-H 
stage II CRC patients have been found not to benefit from adjuvant 5-FU based 
chemotherapy (Sargent et al. 2010). MSI-testing aids in selecting adjuvant 
treatments for stage II CRC patients, since patients diagnosed with MSI-H tumours 
can be excluded from those in potential need of adjuvant chemotherapy (Copija et 
al. 2017). Stage IV disease rarely presents with MSI-H phenotype (Koopman et al. 
2009). However, if this happens, MSI-H stage IV CRC patients can be candidates 
for treatment with immune check-point inhibitors, and promising results have been 
seen in preliminary treatment trials (Gourd 2018). 
2.7.2 Tumour budding and related markers 
In CRC, the invasive tumour margin morphology may give a clue to 
aggressiveness of cancer, and it may play a role in predicting the risk of relapse 
(Karamitopoulou et al. 2015). Tumour budding (TB) refers to single cancer cells or 
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clusters up to four cancer cells apart in stroma usually at the invasive margin (Ueno 
et al. 2002). There is evidence that TB is linked with EMT, a phenomenon 
associated with the metastasizing process (Grigore et al. 2016). In several 
publications, TB has been reported to be associated with a high TNM stage, high 
tumour grade, and presence of local and distant metastasis (Rogers et al. 2016). 
Specifically, it is considered to be an independent predictor of survival in stage II 
CRC, and patients of stage II CRC with high grade TB should be considered to 
receive adjuvant chemotherapy (van Wyk et al. 2015).  
According to International Tumour Budding Consensus Conference (ITBCC) 
guidelines TB is assessed by selecting the hematoxylin eosin (H&E) slide with 
highest amount of TB at the invasive front, the tumour buds are counted from one 
hot spot within 20x objective field, and finally the numerical value is adjusted with 
a correction coefficient to end up in a field of 0.785 mm2 (Lugli et al. 2017). Even 
if the analysis is recommended to be done from H&E slides, cytokeratin 
immunostaining aided method can be used in challenging cases like those with an 
abundant disturbing inflammatory reaction in the invasive front (Koelzer et al. 
2016; Lugli et al. 2017; Mehta et al. 2018).  
EMT is a complex process, during which the epithelial cells acquire features 
that are typical of mesenchymal cells, and EMT is seen in both normal 
physiological and pathological processes like in cancer (Nakaya et al. 2013). In 
CRC, it has been associated with increased invasiveness and metastasizing 
potential, cancer progression, and treatment resistance (Vu and Datta 2017, Bhangu 
et al. 2012). During EMT the membranous E-cadherin of cancer cells is down-
regulated accompanied by loss of intercellular epithelial junctional complexes 
(Chand et al. 2018). In addition, several other genes with a fundamental role in 
EMT are known (Figure 1.). There are several reports, which show EMT to be 
involved in TB (Grigore et al. 2016). Since TB is of clinical significance even in 
stage II CRC, markers of EMT may have an increasing prognostic role in CRC 
even in the near future. This concerns especially integrin beta 4 (ITGB4), which we 
propose to be a potential surrogate marker of TB in cases where tissue tumour 
material is too scarce for conventional TB analysis (Original publication II).  
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Figure 1.  Molecular biological changes in cells during EMT. There is progressive loss of 
epithelial features and gain of mesenchymal features. The differentiation of cancer 
cells with mesenchymal features back to epithelial cells, mesenchymal-epithelial 
transition (MET) is a less known phenomenon. Printed from Dongre A, Weinberg RA. 
(2019) New insights into the mechanisms of epithelial-mesenchymal transition and 
implications for cancer. Nat Rev Mol Cell Biol 20(2): p. 70. Reprinted with permission 
of Springer Nature to be used in Khadija M Slik’s thesis. 
2.7.3 Ezrin 
Ezrin belongs to Ezrin, Radixin, and Moesin (ERM) complex, and it combines the 
actin cytoskeleton to a variety of membrane-bound receptors and adhesion 
molecules (Neich et al. 2011). It participates to cell migration, proliferation, 
survival, and signal transduction including mammalian target of rapamycin 
(mTOR), phosphatidylinositol-3 kinase (PIK3K)/Akt, Src, EGFR, Rho-kinase, and 
protein kinase C pathways (Brambilla et al. 2009). In malignant cells it has a role 
in motility, invasion, metastatic potential and survival of malignant cells through 
the counteracting of inhibitors of apoptosis proteins (IAPs), X-linked inhibitor of 
apoptosis protein (XIAP) and survivin (Leiphrakpam et al. 2018). High Ezrin 
protein expression is associated with poor survival in several cancers including 
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CRC (Li et al. 2015; Elzagheid et al. 2008; Mori et al. 2017; Original publication 
I). In CRC, ezrin protein expression has been associated with grade, stage, lymph 
node and distant metastasis, and survival (Liang et al. 2017). 
2.7.4 CDX2 
Caudal-related homeobox transcription factor 2 (CDX2) encoded by CDX2 gene, 
is vital for intestinal development and differentiation (Olsen et al. 2014; Verzi et al. 
2011). Positive nuclear staining of CDX2 in carcinomas refers to their possible 
origin from gastrointestinal tract (De Lott et al. 2005). That is why this antibody 
can be used in clinical pathology marker panels for carcinomas of unknown 
primary (Varadhachary et al. 2008). There are some rather convincing reports 
concerning the association of CDX2 loss and poor prognosis in colorectal cancer 
(Dalerba et al. 2016). However, the prognostic significance of CDX2 staining 
pattern has not yet been specifically studied in stage II colorectal cancer. 
2.7.5 Others 
The sidedness of CRC affects its presentation and clinical outcome (Lee et al. 
2015). The right-sided colon cancers manifest with less and more obscure 
symptoms than left-sided colon cancer, which may cause the diagnosis of those 
with right-sided cancer to be made at a more advanced stage (Nawa et al. 2008). 
There are significant differences in expression profiles of more than 1000 genes 
between the right and left-sided colon (Glebov et al. 2003). Of environmental risk 
factors, high meat consumption increases the risk of left-sided colon cancer more 
than that of right-sided (Larsson et al. 2005). Right-sided colon cancer has inferior 
prognosis compared with left-sided colon cancers, which may be related with 
histopathological factors, including poor differentiation grade, molecular genetic 
factors, and difficulties to diagnose right-sided cancer at an early stage (Nitsche et 
al. 2016; Baran et al. 2018). In stage II CRC, the right-sided cancer is associated 
with favorable prognosis, while after disease recurrence it is a sign of poor 
prognosis (Kennecke et al. 2018). This may be associated with overrepresentation 
of MSI-H tumours on the right side, which are known to behave in an indolent way 
in early stages (Battaglin et al. 2018).  
Consensus Molecular Subtypes (CMS) refers to sorting of CRCs to four groups 
according to their molecular pathological features (Fontana et al. 2019). These four 
CMS groups include: CMS1 (MSI-immune, 14 %) hypermutated cancers, which 
are characterized by MSI-H phenotype, CIMP-high and BRAF-mutation; CMS2 
(canonical, 37 %) cancers are characterized by high number of somatic gene copy 
number alterations, activation in WNT and MYC; CMS3 (metabolic, 13 %) 
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cancers often carry KRAS-mutation and metabolic deregulation; CMS4 
(mesenchymal, 23 %) cancers have high number of somatic gene copy alterations, 
transforming growth factor beta (TGF-β) activation and EMT. In addition, there is 
an unclassified mixed group (13 %). (Müller et al. 2016). In stage II CRC, CMS4 
cancers carry an unfavorable prognosis, since they have a high rate of TB (Trinh et 
al. 2018).  
Some gene panels have been made to identify CRC patients with poor 
prognosis, especially to recognize high risk stage II CRC patients in need of 
adjuvant chemotherapy. ColonPrint uses an 18-gene assay (Salazar et al. 2011), 
and Oncotype DX includes seven cancer-related genes (O’Connell et al. 2010). In 
one more recent study using an expression profile of 120 genes (Lin et al. 2017), 
the outcome of stage I-II CRC patients could be predicted with high efficacy. 
However, only recently the significance of gene panels has gradually been 
increasing in clinical practice. Along with the increasing importance of precision 
oncology, especially next-generation-sequencing (NGS) has identified new 
potential treatment targets of CRC, which could help to improve disease outcome, 
especially among patients with stage IV disease (Rachiglio et al. 2019). Also, in 
differential diagnosis of poorly differentiated malignant neoplasms, cancer gene 
panes may be useful (Ericson-Lindquist et al. 2017).  
Cancer stem cells and EMT are both thought to be related with chemo 
resistance in CRC (Boesch et al. 2018). Cancer stem cells are a minority of tumour 
cells, which are able to self-renew and differentiate (Clarke et al. 2006). Cancer 
stem cells have also been observed to be more chemo- and radioresistant than other 
cells of the tumour (Makena et al. 2018). CRC stem cells can be identified with 
their cell surface molecules: CD44, CD133, CD166, leucine-rich repeat-containing 
G-protein (Lgr5) and aldehyde dehydrogenase 1 (ALDH1) (Zhou et al. 2017). 
Although there are some reports of using these markers in the prognostic 
assessment of even early CRC (Avoranta et al. 2013), they have not been 
established yet in clinical use.  
MicroRNAs are small non-coding RNA molecules, which have a role in the 
regulation of gene expression (Bartel 2004). There are several reports showing that 
dysregulation of microRNAs has a crucial role in neoplastic transformation, cancer 
progression and invasion including CRC (Chen et al. 2016). A combination of 
selected microRNAs has shown its ability to detect even early-stage CRC (Guo et 
al. 2018). However, it is not easy to transfer their use to a clinical practice. For 
instance, there are several interfering tissue sources for microRNAs, which 
deteriorate their reliability as a tool for clinical cancer prognosis setting (Chen et al. 
2019).  
There is evidence that the host immune response plays a role in the outcome of 
cancer patients (Lu et al. 2006). Specifically, activation of systemic inflammatory 
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response has been linked with tumour progression, regardless of TNM-class 
(Roxburg & McMillan 2014). To evaluate this inflammatory response some simple 
and easily reproducible methods have been developed, such as Glasgow prognostic 
score (GPS). This score is estimated according to serum CRP and plasma albumin 
levels (McMillan 2013). According to one study with stage II CRC patient cohort, 
DSS was worse among patients with GPS 2, as compared to those who had GPS 0 
or 1 (Sugimoto et al. 2012). Also, a meta-analysis supports the significance of GPS 
for survival of CRC (Lu et al. 2018). Also, neutrophil-to-lymphocyte ratio (NLR) 
and platelet-to-lymphocyte ratio (PRL) have been shown to correlate with survival 
in CRC (Kwon et al. 2012). The host immune response in cancer patients can also 
be studied using paraffin-embedded tumorous tissue material. Among one of the 
most applied methods for this is the Immunoscore (IS) system, which utilizes 
tumour infiltrating lymphocytes (Galon et al. 2006). More specifically, the density 
of CD3+ and CD8+ tumour infiltrating lymphocytes are evaluated in tumour center 
and tumour invasive front areas (Galon et al. 2014). There are several studies that 
support the ability of Immunoscore to predict the outcome in colorectal cancer 
diagnosed at any stage (Sun et al. 2018), and this result has also been verified in a 
large international consortium study (Pagès et al. 2018). 
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3 Aims 
The current means to predict the behavior of stage II CRC are insufficient. A 
significant proportion of relapses are diagnosed in stage II patients without any of 
the established high risk factors including lymphovascular invasion, poor 
differentiation grade, emergency operation, obstruction, perforation and less than 
12 examined lymph nodes (Dotan & Cohen 2011; Liebig et al. 2009; Labianca et 
al. 2013; O’Connor et al. 2011). During the last few years some new biomarkers 
have been introduced, namely evaluation of MSI status and TB (Ribic et al. 2003; 
Siniscrope et al. 2011; Mitrovic et al. 2012; Lugli et al. 2017). Although they help 
to identify some additional stage II CRC patients, who could benefit from adjuvant 
therapy, new biomarkers are still required to further improve patient selection for 
those, who could get the best advantage from postoperative adjuvant treatments. 
The focus of this study is to evaluate new promising biomarkers for this purpose. 
In this study we have evaluated biomarkers related with epithelial integrity (ezrin 
and CDX2), TB and a phenomenon related to it: epithelial to mesenchymal 
transition. We have correlated our results in relation to clinicopathological 
variables including MSI status and BRAF-mutation status.  
The specific aims of the study with materials of stage II colorectal cancer 
patients are:  
1) To analyze ezrin protein expression with tissue microarray (TMA) and 
to correlate the results with MSI and BRAF mutation status and 
clinicopathological variables  
2) To compare the prognostic efficacy of TB analyzed visually from 
routine stained (HE) whole slides to that of selected EMT markers 
analyzed from TMA slides with image analysis.  
3) To estimate the ability of CDX2 protein expression profile to predict 
patient outcome. 
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4 Patients and Methods 
4.1 Patients 
This retrospective study included histological material from two patient cohorts 
(Table 2). All studies in this thesis work (I–III) included tissue material from 232 
stage II CRC patients treated at Turku University Hospital between the years 2005–
2012. One study (II) also included material from 72 consecutive stage II (Dukes B) 
CRC patients treated at Helsinki University Hospital between the years 1998–2000. 
The use of paraffin-embedded material from these patients was approved by 
National Supervisory Authority of Welfare and Health (Valvira Dnro 
4423/32/300/02 and 10041/06.01.03.01/2012). For the cohort of patients from 
Turku permission from Turku University Hospital was approved (T52/2014), and 
the use of tissue material was also approved by Scientific Steering Group of Auria 
Biobank (AB15-8108, 25.5.2015). For Helsinki cohort a permission from local 
ethical committee (Dnro HUS 226/E6/06, extension TMK02 §66 17.4.2013) was 
approved. To exclude distant metastasis, CT of the abdomen and chest x-ray or 
whole-body CT were preoperatively performed. The patient files have been 
carefully checked, including surgery and pathology reports. Patients with lymph 
node or distant metastases were excluded as well as those who had been operated 
with palliative-intent surgery and patients with other than adenocarcinoma 
histology. TNM7 classification of malignant tumours was used for staging, as this 
staging was in use at that time, Table 3. 
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Table 2.  Clinical characteristics of the patients in the original publications. 
 Cohort of Turku University Hospital  
n = 232 (I–III) 
Cohort of Helsinki University 
Hospital 
n = 72 (II) 
5-year OS 
5-year DFS 
5-year DSS 
 
80.1 % 
86.9 % 
91.1 % 
 66.70 % 
 
80.60 % 
Age 
Median 
Range 
  
 
 
 
<70 
>70 
 
74 
34–96 
92 
140 
 
 
 
<65 
>65 
 
72 
35–94 
24 
48 
Gender 
Female 
Male 
 
  
 
117 
115 
 
 
 
29 
43 
Tumour side 
Right 
Left 
 
 
112 
12 
 
 
20 
52 
pT-status 
T3N0 
T4aN0 
T4bN0 
 
 
190 
21 
21 
Duke’s 
classification Dukes B 
Grade 
G1 
G2 
G3 
n.d. 
 
 
21 
154 
51 
1 
 
G1-2 
 
G3 
n.d. 
 
58 
 
13 
1 
Histology 
Conventional 
Mucinous 
n.d. 
 
 
205 
26 
1 
 
 
68 
4 
 
Preoperative 
obstruction 
No 
Yes 
 
 
 
196 
36 
  
Tumour perforation 
No 
Yes 
n.d. 
 
 
212 
19 
1 
  
Radicality 
R0 
R1 
R2 
n.d.  
 
214 
15 
3 
 
 
27 
6 
0 
39 
MSI status 
MSS 
MSI-H 
n.d. 
 
 
171 
43 
18 
  
BRAF status 
WT 
V600E 
n.d. 
  
183 
28 
21 
  
N.d., not determined. Modified from original publication II, p. 65 and supplementary material of 
original publication II, p. 14. Creative Commons license, authors are the copyright holders. 
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Table 3.  TNM classification of colon and rectum carcinoma used in the original publications, 7th 
edition. 
T-Primary Tumour N-regional Lymph nodes 
Tx Primary tumour cannot be assessed Nx Regional lymph nodes cannot be 
assessed 
T0 No evidence of primary tumour N0 No regional lymph node metastasis 
Tis1 Carcinoma in situ: intraepithelial or 
invasion of lamina propria 
N1 Metastasis in 1–3 regional lymph nodes 
N1a Metastasis in 1 regional lymph 
node 
N1b Metastasis in 2–3 regional lymph 
nodes 
N1c Tumour deposit(s), i.e. satellites*, 
in the subserosa, or in non-
peritonealized pericolic or perirectal 
soft tissue without regional lymph 
node metastasis 
  N2 Metastasis in 4 or more regional 
lymph nodes 
N2a Metastasis in 4–6 regional lymph 
nodes 
N2b Metastasis in 7 or more regional 
lymph nodes 
T1 Tumour invades submucosa   
T2 Tumour invades muscularis propria   
T3 Tumour invades subserosa or into the non-
peritonealized pericolic or perirectal tissues 
  
T4 Tumour directly invades other organs or 
structures and/or perforates visceral 
peritoneum 
T4a Tumour perforates visceral 
peritoneum 
T4b Tumour directly invades other organs 
or structures2,3 
  
 Notes:  Notes: 
1. Tis includes cancer cells confined within 
the glandular basement membrane 
(intraepithelial) or mucosal lamina propria 
(intramucosal) with no extension through 
the muscularis mucosae into the 
submucosa. 
 *Tumour deposits (satellites), i.e. 
macroscopic or microscopic nests or 
nodules, in the pericolorectal adipose 
tissue’s lymph drainage area of a primary 
carcinoma without histological evidence 
of residual lymph node in the nodule, may 
represent discontinuous spread, venous 
invasion with extracellular spread /V1/2) 
or a totally displaced lymph node (N1/2). 
If such deposits are observed with lesions 
that would otherwise be classified as T1 
or T2, then the classification is not 
changed, but the nodule(s) is recorded as 
N1c. If a nodule is considered by the 
pathologist to be totally replaced lymph 
node (generally having a smooth 
contour), it should be recorded as a 
positive lymph node and not as a satellite, 
and each nodule should be counted 
separately as a lymph node in the final 
pN determination. 
2. Direct invasion in T4b includes invasion of 
other organs or segments of the 
colorectum by way of the serosa, as 
confirmed on microscopic examination or 
for tumours in a retroperitoneal or 
subperitoneal location, direct invasion of 
other organs or structure by virtue of 
extension beyond the muscularis propria. 
 
3. Tumour that is adherent to other organs or 
structures, macroscopically, is classified 
cT4b. However, if no tumour is present in 
the adhesion, microscopically, the 
classification should be pT1–3, depending 
on the anatomical depth of wall invasion. 
 
   M – Distant Metastasis 
   Mx Distant metastasis cannot be 
assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to one 
organ or site (eg. liver, lung, ovary, 
non-regional nodes) 
M1b Metastases in more than one 
organ/site or the peritoneum 
*According to Sobin L, Gospodarowicz MK, Wittekind C (eds). The TNM Classification of 
Malignant Tumours, 7th Edition. Singapore: Wiley-Blackwell; 2010, pp. 102–103. Reprinted with 
permission from John Wiley & Sons Limited to be used in Khadija M Slik’s thesis. 
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4.2 Methods 
4.2.1 Constructing of tissue microarray (I–III) 
For TMA the next-generation TMA technique was used (Zlobec et al. 2013). 
Shortly, the suitable paraffin blocks with tumorous tissue were selected from each 
case and H&E sections of them were cut. The slides were scanned (Pannoramic 
P250, 3DHistech) and saved into the university digital microscopy server 
(casecenter.utu.fi). To analyze them, Pannoramic Viewer software (3DHistech) 
was used. With the 1.2 mm diameter annotation tool, circles of different colours 
corresponding to center of tumour, front of tumour and normal colonic epithelium 
were done. The corresponding tissue cores were shifted to the TMA blocks with 
automated TMA machinery (TMA Grandmaster, 3DHistech). The completed TMA 
blocks were cut, stained, scanned and moved into the server (casecenter.utu.fi). 
4.2.2 Primary antibodies and staining methodology (I–III) 
The sections of 3,5 μm thickness were made from TMAs. They were subjected to 
concerned primary antibodies (Table 4). BenchMark XT (Ventana/Roche) 
immunoautomate was used with UltraView Universal diaminobenzidine (DAB) 
Detection kit or OptiView Universal DAB Detection kit. For ezrin staining 
LabVision immunoautomate (Thermo Fisher Scientific) was used with the Power 
Vision Plus poly HRP antimouse/rabbit/rat IgG detection kit. 
Table 4.  Primary antibodies used in the thesis  
Study Antigen target Clones Dilution Provider 
I MLH1 
MSH2 
MSH6 
PMS2 
BRAF V600E 
Ezrin 
G168-15BD 
G219-1129 
EP49 
EPR3947 
VE1 
3C12 
1:5 
1:200 
1:200 
Ready to use 
Ready to use 
0.3mg/mL 
Pharmingen 
Pharmingen 
Epitomoc 
Ventana/Roche 
Ventana/Roche 
Böhling et al. 1996 
II Pancytokeratin 
 
 
 
ZO-1 
Integrin 4ß 
E-cadherin 
C-11, ab7753 
 
AE1/3, MA5-13156 
 
D7D12 
D8P63 
36 
1:1500 
 
1:1000 
 
1:500 
1:100 
1:200 
Thermo Fisher 
Scientific 
Thermo Fischer 
Scientific 
CST 
CST 
BD 
III CDX2 EPR2764Y Ready to use Roche Diagnostics 
CST, Cell Signaling Technology; BD, BD Bioscience 
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In thesis work II the primary antibodies of multiplex IHC were detected using 
tyramide signal amplification (TSA): AlexaFuor488 for Pancytokeratin antibodies, 
AlexaFluor555 for ZO-1 antibody and AlexaFuor 647 for Integrin ß4 and E-
cadherin antibodies (Thermo Fisher Scientific, Invitrogen). The staining 
methodology has been presented in detail in the original publications (I–III). 
4.2.3 Evaluation of immunohistochemical stainings (I–III) 
MLH1, MSH2, MSH6, PMS2 and BRAF-mutation stainings were assessed 
dichotomously as positive or negative. Positive nuclear reaction in all four MSI 
immunohistochemical stainings refers to MSS phenotype, while the following 
patterns refer to MSI high phenotype: negative for MLH1/PMS2, negative for 
MSH2/MSH6, negative for MSH6 and negative for PMS2 (Overbeek et al. 2008). 
For BRAF V600E mutation staining, a cytoplasmic reaction was recognized. For 
ezrin staining, bulk and front cores were evaluated separately and the strongest 
staining was considered. Four staining categories were recognized: negative, weak 
positive, moderate positive and strong positive, and for statistical purposes also 
dichotomous categories, negative / weak and moderate / strong, were used. CDX2 
was first assessed in four categories from each spot: 0 (negative), 1 (weak), 2 
(moderate) and 3 (strong). Thereafter, mean values were counted from staining 
intensities in replicate two spots (front and bulk cores were evaluated separately) as 
follows: 0–0.5 = 0 (negative), 1–1.5 (weak) and 2–3 = 2 (conventional). For 
statistical purposes, dichotomous categories of CDX2 loss (negative / weak) and 
conventional were used. For E-cadherin, ZO-1, ITGB4 and Pancytokeratin: digital 
image analysis was used (see 4.2.4). The immunohistochemical slides were 
reviewed by 2 independent evaluators, and consensus formed from discrepant 
cases. 
4.2.4 Visual TB analysis (II) 
TB was evaluated according to the instructions of the ITBCC 2016. Shortly, 1–4 
buds in hot spot of 20x objective field (0.792 mm2) corresponds to bd1, 5-9 buds 
to bd2 and 10 or more buds to bd 3. (Lugli et al. 2017). TB was analyzed visually 
from H&E stained whole sections and TMAs, and also from CkPan stained TMAs. 
4.2.5 Digital image analysis (II) 
TB was digitally analyzed from TMAs stained with multiplex IHC including EMT 
markers E-cadherin, ITGB4, ZO-1, and pan-cytokeratin. The multiplex IHC was 
done as previously described in Blom et al. (2017) using fluorescently labelled 
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secondary antibodies. Five-channel fluorescent images were generated with the 
Metafer 5 scanning and imaging system (MetaSystems, Germany), with a ×20 
objective (NA 0.8). TIFF images were downscaled to 1:4 from the original 
resolution for image analysis (final resolution 0.88 μm/pixel), and cell image 
analysis software was used (CellProfiler version 2.2.0; Carpenter et al. 2006). Its 
main phases include: (1) spot perception, (2) epithelial cluster and bud perception, 
(3) determination of channel intensities, and (4) data export (Figure 2). The image 
analysis protocol has been presented in detail in original publication (II). 
 
 
Figure 2.  The multiplex IHC platform used in the original publication II includes easy selection of 
the relevant antibodies (a), multiplex ICH assay, (b), high-resolution whole-slide image 
scanning, and high-resolution whole-slide image analysis of open source (c-d). Blom 
S, Paavolainen L, Bychkov D, et al. Systems pathology by multiplexed 
immunohistochemistry and whole-slide digital image analysis. Sci Rep 2017; 7: 15580, 
p. 7. Reprinted with Creative Commons license: http://creativecommons.org/ 
licenses/by/4.0. 
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4.2.6 Statistical analysis (I–III) 
Statistical analyses were made with IBM SPSS version 23-24 with standard 
packages (SPSS Inc., Armonk, NY, USA). Normality of the data was assessed with 
the Kolmogorov–Smirnov test. The correlations between immunohistochemical 
staining and clinicopathological variables were analyzed with χ2 or Fisher's exact 
test for discrete variables and one-way ANOVA for continuous variables. In the 
original publication II correlations were evaluated with the non-parametric two-
tailed Spearman rho test, and p values for mean and median comparisons were 
analyzed with either the Student’s t test (normal distribution) or the Mann–Whitney 
U test (non-normal distribution). The Cox proportional hazard regression model 
and the Kaplan-Meier analysis with log-rank test for survival analysis were made 
with the aid of R version 3.4.3 (Foundation for Statistical Computing, Vienna, 
Austria) and RStudio 1.1.383 (RStudio Inc, MA, Boston, USA) with survival 
package 2.41-3. The methodology of statistical analyses has been presented in 
detail in original publications I-III. 
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5 Results 
5.1 Ezrin in relation to clinicopathological 
characteristics and survival in stage II 
colorectal cancer (I) 
High ezrin protein expression was more often seen in tumours with MSI-H 
phenotype than that with MSS tumours. In addition, high ezrin expression 
correlated with short disease-specific survival (DSS) (Table 5.). The ability of ezrin 
expression to identify high risk patients was strengthened by combining it to MSI-
status. Specifically, when considering 5-year DSS time, patients with low ezrin 
expression and MSI-H had better survival when compared to patients with high 
ezrin expression and MSS (11/18 (61 %) vs. 4/18 (21 %), p = 0.040, Fisher’s exact 
test). In Kaplan-Meyer survival analysis the patients, who had low ezrin expression 
and MSI-H phenotype had the longest DSS and those with high ezrin expression 
and MSS phenotype the shortest (p = 0.007, log-rank test, Figure 3).  
In multivariate analysis, high ezrin expression with MSS phenotype, as well as 
tumour perforation were independent factors of poor DSS (Table 6.). Independent 
factors of poor overall survival included tumours with T4bN0, perforation and 
BRAF-mutation (Cox model, hazard ratio (HR) 2.86, 95 % confidence interval 
(CI): 1.06–7.74, p = 0.038; HR 3.8, 95 % CI: 1.57–9.17, p = 0.003; and HR 3.29, 
95 % CI: 1.14-9.54, p= 0.028), respectively. Independent factors of poor DFS 
included tumours with T4bN0, vascular invasion and perforation (Cox model, HR 
8.05, 95 % CI: 2.31–28.01, p = 0.001; HR 3.62, 95 % CI: 1.26–10.37, p = 0.017; 
and HR 4.87, 95 % CI: 1.38–17.23, p = 0.014), respectively. The results have been 
presented in more detail in the original publication (I). 
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Table 5.  Ezrin expression in relation to MSI- and BRAF mutation status and survival. 
Variable Ezrin low, n (%) Ezrin high, n (%) Significance (p)* 
Study population (n = 173)    
MSI status 
MSS 
MSI 
 
117 (87) 
18 (13) 
 
19 (50) 
19 (50) 
0.001 
BRAF status 
BRAF WT 
BRAF mutated 
 
121 (91) 
12 (9) 
 
25 (66) 
13 (34) 
0.001 
Disease-specific outcome 
Alive without CRC 
Alive with CRC 
Dead of CRC 
Dead of other cancer 
Dead of other causes 
Dead cause unspecified 
 
93 (69) 
3 (2) 
8 (6) 
16 (12) 
11 (8) 
4 (3) 
 
23 (61) 
0 (0) 
9 (24) 
2 (5) 
4 (11) 
0 (0) 
0.038 
*Pearson’s chi-square test. Modified from original publication I, p. 8. Creative Commons license, 
authors are the copyright holders. 
 
Figure 3.  Disease-specific survival of patients with regard to ezrin protein expression and MSI-
status. Modified from original publication I, p. 11. Creative Commons license, authors 
are the copyright holders. 
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Table 6.  Univariate and multivariate Cox regression analysis (DSS) according to selected 
clinicopathological variables, MSI-status and ezrin protein expression.  
Variable Univariate HR 
(95 % CI) 
p-value Multivariate HR  
(95 % CI) 
p-value 
Stage 
T3N0  
T4aN0 
T4bN 
 
1 (ref) 
2.35 (0.65–8.41) 
3.96 (1.1–14.24) 
 
 
0.19 
0.035 
 
1 (ref) 
3.40 (0.72–15.98) 
4.58 (0.89–23.62) 
 
 
0.121 
0.069 
Perforation 
No  
Yes  
 
1(ref) 
6.44 (2.25–18.41) 
 
 
0.001 
 
1 (ref) 
5.44 (1.3–22.75) 
 
 
0.002 
Ezrin & MSI status 
Ezrin low MSS 
Ezrin low MSI 
Ezrin high MSS 
Ezrin high MSI 
 
1 (ref) 
0.00 (0.00–0.00) 
4.00 (1.31–12.23) 
3.6 (1.08–11.96) 
 
 
0.983 
0.015 
0.037 
 
1 (ref) 
0.00 (0.00–0.00) 
5.68 (1.53–21.12) 
3.19 (0.61–16.74) 
 
 
0.986 
0.01 
0.17 
Ref, reference category; n.d., not determined. Modified from original publication I, page 11 and 
supplementary Table S1. Creative Commons license, authors are the copyright holders. 
5.2 Tumour budding and EMT marker integrin 4 
beta in relation to clinicopathological 
characteristics and survival in stage II 
colorectal cancer (II) 
In three-tiered scoring of TB assessed visually from HE stained whole sections the 
patients with Bd2 and Bd3 had shorter DSS compared to Bd1 patients. In 
multivariate analysis Bd2 only but not Bd3 was an independent factor of poor DSS, 
as well as T4N0 tumours, perforation and vascular invasion (Table 7.). The power 
of TB as a prognostic factor of poor DSS became even more evident, when 2-
tirered scoring was used as seen in univariate analysis (HR 7.55; 95 % CI: 2.64–
18.28, p < 0.001, Figure 4.), and also in multivariate analysis (HR 6.04; 95 % CI: 
2.00–18.20, p = 0.001). In multivariate analysis including TB with two-tiered 
scoring other independent factors of poor DSS included T4N0 stage, and vascular 
invasion (Table 8.).  
The digitally analyzed buds with high integrin beta 4 expression (ITGB4-high 
bud, higher than median intensity in all epithelial clusters in the full cohort) was 
prognostic factor of poor DSS in univariate analysis, and it also turned out to be an 
independent factor of poor DSS in multivariate analysis together with T4N0 stage, 
perforation and vascular invasion (Table 9.). The same result was obtained when 
ITGB4-high buds were analyzed from a validation cohort with patients treated in 
Helsinki University Hospital (HR 3.61; 95 % CI: 1.34–9.74; Helsinki cohort). 
Strong ITGB4 expression in tumour buds coincided with a localization switch of 
ITGB4 from basal membrane and cell-cell contacts of intact epithelium to diffusely 
fill cytoplasm of the budding tumour cells. In addition, small tight junction 
perimeter (ZO-1 staining) and loss of E-cadherin correlated with strong expression 
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of ITGB4 in tumour buds. In addition, ITGB4 high-bud count analyzed from TMA 
material with image analysis correlated better with visually scored TB analysis 
from H&E stained whole sections than any of the other tested TB scoring methods. 
These include: visually scored TB analysis from H&E stained TMAs, visually 
scored TB analysis from pancytokeratin (CkPan) stained TMAs, and TB digital 
analysis without ITGB4-evaluation. The results of visual and digital TB analyses 
have been described in more detail in the original publication (II). 
Table 7.  Univariate and multivariate Cox regression analysis (DSS) for visually assessed TB 
(three-tier) and for selected clinicopathological variables and biomarkers with statistical 
significance. 
Variable Univariate HR 
(95% CI) 
p-value Multivariate HR 
(95% CI) 
p-value 
TB H&E 
Bd 1 (n = 192) 
Bd2 (n = 24) 
Bd3 (n = 16) 
n.d. = 2 
 
1 (ref) 
6.95 (2.64–18.78) 
5.55 (2.00–15.44) 
 
 
8.48E-05 
0.0010 
 
1 (ref) 
5.63 81.63–19.39) 
3.13 (0.91–10.70) 
 
 
0.0062 
0.069 
pT-status 
T3N0 (n = 78) 
T4abN0 (n = 142) 
 
1 (ref) 
3.02 (1.38–6.62) 
 
 
0.006 
 
1 (ref) 
4.38 (1.54–12.46) 
 
 
0.0056 
Perforation 
No (n = 203) 
Yes (n = 18) 
n.d. = 12 
 
1 (ref) 
4.39 (1.76–10.95) 
 
 
0.0015 
 
1(ref) 
4.04 (1.18–13.82) 
 
 
0.0259 
Radicality 
R0 (n = 203) 
R1 (n = 14) 
R2 (n = 3) 
n.d. = 12 
 
1 (ref) 
0.59 (0.08–4.37) 
15.71 (3.61–68.35) 
 
 
0.606 
0.0002 
 
n.d. 
n.d. 
n.d. 
 
Vascular invasion 
No (n = 171) 
Yes (n = 37) 
n.d. = 12 
 
1(ref) 
2.10 (0.92–4.80) 
 
 
0.0789 
 
1(ref) 
3.57 (1.33–9.55) 
 
 
0.0114 
Ezrin 
Low (n = 98) 
Intermediate (n = 36) 
High (n = 38) 
n.d. = 48 
 
1 (ref) 
1.39 (0.42–4.62) 
3.19 (1.19–8.54) 
 
 
0.5895 
0.0209 
 
n.d. 
n.d. 
n.d. 
 
Ref, reference category; n.d., not determined. Modified from original publication II, page 67. 
Creative Commons license, authors are the copyright holders. 
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Figure 4.  Disease-specific survival of patients with regard to TB has been evaluated visually 
from HE-stained whole sections (2-tiered scoring). Reprinted from original publication 
II, page 66. Creative Commons license, authors are the copyright holders.   
Table 8.  Univariate and multivariate Cox regression analysis (DSS) for visually assessed 
tumour budding (2-tier) and for selected clinicopathological variables.  
Variable Univariate HR 
(95% CI) 
p-value Multivariate HR (95% 
CI 
p-
value 
TumourBudding 2-
tier 
Bd 1 (n = 192) 
Bd2 (n = 24) 
n.d. = 12 
 
 
1 (ref) 
7.55 (2.64–18.28) 
 
 
 
7.75E-07 
 
 
1(ref) 
6.04 (2.00–18.20) 
 
 
 
0.001 
pT-status 
T3N0 (n = 178) 
T4abN0 (n = 142) 
 
1 (ref) 
3.02 (1.38–6.62) 
 
 
0.006 
 
1(ref) 
4.12 (1.53–11.14) 
 
 
0.005 
Perforation 
No (n = 203) 
Yes (n = 18) 
n.d. = 12 
 
1(ref) 
4.39 (1.76–10.95) 
 
 
0.0015 
 
1(ref) 
2.93 (0.84–10.26) 
 
 
0.093 
Radicality 
R0 (n = 203) 
R1 (n = 14) 
R2 (n = 3) 
n.d. = 12 
 
1(ref) 
0.59 (0.08–4.37) 
15.71 (3.61–68.35) 
 
 
0.606 
0.0002 
 
n.d. 
n.d. 
n.d. 
 
Vascular invasion 
No (n = 171) 
Yes (n = 37) 
n.d. = 12 
 
1(ref) 
2.10 (0.92–4.80) 
 
 
0.0789 
 
1(ref) 
3.27 (1.20–8.94) 
 
 
0.021 
Ref, reference category; n.d., not determined. Modified from original publication II, supplementary 
Table S1. Creative Commons license, authors are the copyright holders. 
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Table 9.  Univariate and multivariate Cox regression analysis (DSS) for ITGB4-high bud count 
(2-tier) and for selected clinicopathological variable and biomarkers with statistical 
significance. 
Variable Univariate HR 
(95% CI) 
p-value Multivariate HR 
(95% CI 
p-value 
ITGB4-high buds 
Low (N = 197) 
High (n = 19) 
n.d. = 16 
 
1 (ref) 
5.09 (2.12–12.22) 
 
 
 
0.0003 
 
 
1 (ref) 
4.50 (1.50–13.50) 
 
 
0.007 
Stage 
T3N0 (n = 178) 
T4abN0 (n = 142) 
 
1 (ref) 
3.02 (1.38–6.62) 
 
 
0.006 
 
1(ref) 
5.61 (2.00–15.71) 
 
 
0.001 
Perforation 
No (n = 203) 
Yes (n = 18) 
n.d. = 12 
 
1(ref) 
4.39 (1.76–10.95) 
 
 
0.0015 
 
1(ref) 
3.95 (1.21–12.90) 
 
 
0.0227 
Radicality 
R0 (n = 203) 
R1 (n = 14) 
R2 (n = 3) 
n.d. = 12 
 
1(ref) 
0.59 (0.08–4.37) 
15.71 (3.61–68.35) 
 
 
0.606 
0.0002 
 
n.d. 
n.d. 
n.d. 
 
Vascular invasion 
No (n = 171) 
Yes (n = 37) 
n.d. = 12 
 
1(ref) 
2.10 (0.92–4.80) 
 
 
0.0789 
 
1(ref) 
3.02 (1.15–7.93) 
 
 
0.0245 
Ezrin 
Low (n = 98) 
Intermediate (n = 36) 
High (n = 38) 
n.d. = 48 
 
1 (ref) 
1.39 (0.42–4.62) 
3.19 (1.19–8.54) 
 
 
0.58 
0.0209 
 
n.d. 
n.d. 
n.d. 
 
Ref, reference category; n.d., not determined. Modified from original publication II, page 73. 
Creative Commons license, authors are the copyright holders. 
5.3 CDX2 in relation to clinicopathological 
variables and survival in stage II colorectal 
cancer (III) 
As a categorical variable, CDX2 loss correlated with right-sided tumour, T4N0 
stage, tumour perforation, MSI-status, BRAF-mutation status, poor DFS and DSS, 
high ITGB4 expression in tumour buds, high E-cadherin expression, high tight 
junction perimeter of tumour cells and high ezrin expression. The results of the 
associations concerning CDX2 front cores have been presented in Table 10. The 
results concerning the CDX2 center cores are found in the original publication 
(III).  
When analyzed either from tumour center or front cores, patients with 
disappearance of CDX2 had poor DSS (p = 0.012, log-rank test, Figure 5). The 
same result was obtained concerning DFS (p = 0.004 for tumour center cores,  
p = 0.005 for tumour front cores, log-rank test). In addition, the loss of CDX2 
correlated with poor DSS and DFS only in patients with MSS phenotype  
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(p < 0.001; p = 0.019) but not in patients with MSI-H phenotype (p = 0.21;  
p = 0.14). Finally, CDX2 loss remained an independent factor of poor DSS in 
multivariate analysis concerning both tumour center and tumour front cores (HR 
5.96, 95 % CI: 1.55–22.95; HR 3.70, 95 % CI: 1.30 – 10.56). Other risk factors of 
that Cox model were stage (T3N0 vs. T4N0), number of lymph nodes (>12 vs 
<12), tumour side (left vs. right), tumour perforation (no vs. yes), and TB (<7 vs 
>7). The significant results of CDX2 tumour front core multivariate analysis have 
been presented in Table 11. The results of survival analysis have been presented in 
more detail in the original publication (III). An example of stage II CRC patient 
with several poor prognostic features has been presented in Figure 6. 
 
Figure 5.  Disease-specific survival of patients in relation to CDX2 loss of center TMA cores. 
Reprinted from original publication III, page 1479. Creative Commons license, authors 
are the copyright holders.   
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Table 10.  Association of CDX2 expression (front cores) with selected clinicopathological 
variables and markers related to epithelial integrity and EMT.  
 CDX2 expression 
Variable (n, front core) Low n(%) High n (%) Fisher exact (p) 
Tumour side 
Right (n, 108) 
Left (n, 112) 
 
16 (80) 
4 (20) 
 
83 (46) 
96 (54) 
0.024 
Stage 
T3N0 (n, 178) 
T4abN0 (n, 42) 
 
14 (64) 
8 (36) 
 
150 (84) 
29 (16) 
0.037 
Perforation 
No (n, 203) 
Yes (n, 18) 
 
16 (73) 
6 (27) 
 
168 (94) 
10 (6) 
0.003 
 
MSI status 
MSS (n, 170) 
MSI-H (n, 42) 
 
8 (36) 
14 (64) 
 
150 (84) 
28 (16) 
4.0E-06 
BRAF status 
WT (n, 183) 
V600E (n, 28) 
 
14 (64) 
8 (36) 
 
158 (90) 
18 (10) 
0.003 
TB 
Low Bd<7 (n, 196) 
High Bd>7 (n, 24) 
 
18 (82) 
4 (18) 
 
157 (89) 
20 (11) 
0.313 
Disease-free survival 
No event (n, 182) 
Event (n, 27) 
 
15 (68) 
7 (32) 
 
158 (88) 
21 (12) 
0.019 
 
Disease-specific 
survival 
No event (n, 186) 
Event (n, 23) 
 
16 (73) 
6 (27) 
 
161 (90) 
18 (10) 
0.033 
ITGB4 
Low (n, 110) 
High (n, 106) 
 
5 (23) 
17 (77) 
 
95 (53) 
83 (47) 
0.011 
E-cadherin 
Low (n, 107) 
High (n, 109) 
 
16 (73) 
6 (27) 
 
84 (47) 
94 (53) 
0.040 
TJ perimeter 
Low (n, 108) 
High (n, 108) 
 
16 (73) 
6 (27) 
 
84 (47) 
94 (53) 
0.023 
 
Ezrin1 
Low (n, 98) 
Intermediate (n, 36) 
High (n, 38) 
 
1 (5) 
5 (24) 
15 (71) 
 
90 (63) 
30 (21) 
23 (16) 
2.0E-08 
1Pearson Chi square test has been used for ezrin instead of Ficsher exact probability test. P-
values are 2-sided exact significances. Bolded values mark significance P<0.05.  
Modified from original publication III, pages 1477-1478. Creative Commons license, authors are 
the copyright holders. 
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Table 11.  Multivariate Cox regression analysis (DSS) for CDX2 expression, selected 
clinicopathological variables and TB. 
Variable  
(n front core) 
Multivariate HR  
(95 % CI) 
p-value 
CDX2  
Conventional (n = 191) 
Neg/weak (n=18) 
 
1 (ref) 
3.70 (1.30–10.56) 
 
 
0.014 
Stage 
T3N0 (n = 173) 
T4abN0 (n = 36) 
 
1 (ref) 
2.87 (1.18–6.97) 
 
 
0.02 
Perforation 
No (n = 193) 
Yes (n = 15) 
 
1 (ref) 
3.14 (1.03–9.56) 
 
 
0.045 
TB 
Low Bd < 7 (183) 
High Bd > 7 (24) 
 
1 (ref) 
3.26 (1.21–8.80) 
 
 
0.02 
Ref, reference category. Modified from original publication III, page 1481. Creative Commons 
license, authors are the copyright holders. 
 
Figure 6.  An example of combination of poor prognostic histopathological features in stage II 
colorectal cancer: 6a. MSS phenotype as demontstrated by MLH1 staining; 6b. high 
ezrin protein expression; 6c. BRAF-mutation; 6d. CDX2 loss; 6e TB high; 6f. ITGB4 
high in tumour buds. Figure 6 f. has been modified from the original publication II. 
Creative Commons license, authors are the copyright holders.  
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6 Discussion 
Despite the progress in CRC treatment results, stage II CRC still remains a 
challenge in terms of treatment strategies, and the survival benefit of adjuvant 
chemotherapy is rather modest (Quasar Collaborative Group et al. 2007). The 
addition of MSI-testing (Brierley et al. 2017) and TB (Lugli et al. 2017) analysis 
have helped to some extent in treatment selections, but still new biomarkers are 
needed to identify patients in risk of relapse.  
In this thesis, ezrin and CDX2 protein expression were studied in the material 
of stage II CRC patients treated at Turku University Hospital by constructing a 
TMA from paraffin-embedded tumour material of these patients. The results were 
compared with clinicopathological variables including MSI-status and BRAF-
mutation status. In addition, TB was studied as well as TB-associated EMT-
markers with multiplex-IHC and image analysis including also a validation cohort 
from Helsinki University Hospital. The biomarkers tested are easy to introduce in 
clinical practice of any pathology laboratory with the exception of EMT-markers, 
which still need additional studies to define their applicability for clinical use. 
6.1 Ezrin in relation to prognosis of stage II 
colorectal cancer (I) 
Ezrin belongs to ERM-proteins, which links cell membrane or cell surface 
molecules to cell cytoskeleton (Arpin et al. 2011). For this reason they have a 
crucial effect on neoplastic transformation, cell motility, invasion and metastasis 
(Elliott et al. 2005). In this thesis we have shown, that high ezrin protein expression 
is related with poor prognosis in stage II CRC with microsatellite stable phenotype. 
In previous publications it has turned out to be a factor for poor outcome in several 
malignant neoplasms (Horwitch et al. 2006; Ilmonen et al. 2005; Weng et al. 2005) 
including CRC and other malignancies of the gastrointestinal tract (Arumugam et 
al. 2013;Elzagheid et al. 2008; Korkeila et al. 2011; Ling & Chen 2013; Liang et 
al. 2017). In the study of Ling and Chen 2013 including CRC patients from all 
stages high ezrin protein expression correlated with large tumour size, serosal 
invasion, lymph node metastasis, high lymph node ratio, late tumour stage and 
poor survival. In the current study high ezrin expression correlated with poor DSS 
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(Fisher’s exact test, p = 0.038), and when combined with MSS phenotype, it was an 
independent factor of poor DSS (Cox model, HR 5.68, 95% CI: 1.53–21.12,  
p = 0.01). However, it did not correlate with other clinicopathological variables, 
which may partly be related with the type of patient material including only stage II 
CRC patients. There is evidence, that ezrin does not predict poor outcome in CRC 
in protein level only but also in messenger RNA (mRNA) -level (Mori et al. 2017).  
Which could thus explain the prognostic power of ezrin in a large variety of 
different malignant neoplasms? It is envolved in a variety of processes, which 
favor neoplastic transformation. These include cell signaling pathways including 
protein kinase C, Rho-kinase, NF-ƘB and Pi3 kinase/Akt (Brambilla and Fais 
2009). In addition ezrin is associated with the regulation of several cellular 
processes like cell-cell adhesion, cell motility and invasion (Chuan et al. 2010). 
Ezrin belongs to EMT-promoting proteins, since it is involved in EGFR-NF/kB-
induced activation of EMT (Li et al. 2017). Downregulation of thrombomodulin 
has been shown to correlate with poor outcome in CRC, and the mechanism behind 
this phenomenon has been suggested to result from feed-back upregulation of 
EMT-proteins including ezrin (Chang et al. 2016). In addition, the activity of the 
non-receptor tyrosine kinase proto-oncogene src is promoted by ezrin, which 
contributes to tumorigenesis and metastatic process (Heiska et al. 2011). Still, one 
of the tumour-promoting mechanisms of ezrin may be its suggested inhibitory 
effect on apoptosis in CRC cells (Iessi et al. 2015). Furthermore, ezrin regulates the 
expression of IAPs, XIAP and survivin through protein kinase A (PKA) -
activation, further augmenting its tumorigenic potential (Leiphrakpam et al. 2014; 
Leiphrakpam et al. 2018). 
6.2 Tumour budding and EMT in relation to 
prognosis of stage II colorectal cancer (II) 
It is known that the characterstics of tumour border configuration correlate with 
survival in CRC (Zlobec et al. 2009). More specifically, this concerns the concept 
of TB. It refers to small clusters of up to four cancer cells in tumor stroma, usually 
in the invasive margin (Mitrovic et al. 2012). There are several well documented 
studies indicating the correlation between high grade TB and poor outcome in CRC 
(Rogers et al. 2016). However, it has been problematic to find a consensus for 
standardized assessment of TB in CRC. In 2016 there was a consensus conference 
in Bern of around topic, according to which TB should be assessed primarily from 
H&E stained sections, and from one hot spot at the invasive front using a three-tier 
system bd1-3, where bd3 refers to high grade tumor budding (Lugli et al. 2017). It 
is defined as 10 or more tumor buds counted within one hot spot usually at the 
invasive tumor front using 20 x objective field and the adjustment of the result to 
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the area of 0.785 mm2 (Lugli et al. 2017). The prognostic significance of TB is 
regarded as most remarkable in stage II CRC, where high grade TB is a risk factor 
for a short DFS (Lugli et al. 2017; Wang et al. 2009), and in endoscopically 
resected pT1Nx CRC patients, where high grade TB is a risk factor of lymph node 
metastasis (Ueno et al. 2004; Bosch et al. 2013). For this reason, analysis of TB has 
been included as additional prognostic factor of CRC in TNM8 classification of 
malignant tumours (Brierley et al. 2017). In the original publication II, high grade 
TB in stage II CRC correlated with poor DSS both in univariate (p<0.0001) and 
multivariate analysis. (p=0.006).  
The molecular biological mechanisms behind TB are complex, and not yet 
completely elucidated (Dawson & Lugli 2015). However, there is evidence, that 
TB and EMT are interrelated (Grigore et al. 2016). During this process epithelial 
cells lose their characteristic features including polarity and epithelial integrity, and 
they acquire properties typical of mesenchymal cells allowing them to move and 
increase their invasive potential (Thiery 2002). Therefore, during EMT CRC cells 
lose the expression of epithelial markers including E-Cadherin and they acquire the 
expression of mesenchymal markers like vimentin (Kalluri et al. 2009).  
Since TB itself has already been extensively studied in CRC, we wanted to 
elucidate in more detail the connection between TB and EMT. For this aim we 
used a multiplex IHC and digital image analysis to study immunohistochemical 
profile of tumour buds with TMA material of stage II CRC patients. The selected 
biomarkers included known EMT markers including E-cadherin, ZO-1 and ITGB4. 
The results of digital image analysis from multiplex IHC stained TMAs were 
compared with visual image analysis of TB using either H&E stained serial 
sections from the same TMAs or H&E stained whole sections (cut from 
corresponding donor paraffin blocks of punch tissue cores). Interestingly, the 
multiplex IHC analysis with EMT marker ITGB4 predicted patient survival almost 
as well as visual TB analysis from H&E stained whole sections, where TB was 
estimated with the ITBCC 2016 consensus conference method (Lugli et al. 2017). 
Instead, visual TB analysis from H&E stained serial sections of TMAs did not 
predict survival. This is understandable, since TMAs represent random areas of 
tumour center and front, not hotspot with highest amount of TB. Yet, why does the 
multiplex IHC ITGB4 profile from even these randomly selected tumour areas 
correlate to visually assessed TB? The association of EMT and tumor budding 
(Gurzu et al. 2016) may explain, that overexpression of EMT-associated genes in 
randomly chosen tumor areas even without histologically identifiable tumor buds 
shows correlation with tumor budding evaluated from hot spot area of the same 
tumor. It is possible, that expression level of EMT-proteins might be used as 
surrogate markers of histologically confirmed tumor budding, in small biopsies for 
instance. However, this hypothesis requires further studies.  
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ITGB4 subunit is a transmembrane protein, which forms a heterodimer with the 
α6-integrin subunit to act as a receptor for laminin, and in polarized epithelial cells 
it forms an attachment to basal membrane with the aid of hemidesmosomes 
(Giancotti 2007). For this reason ITGB4 plays a crucial role in several phenomena 
associated with cell migration, growth, and survival (Margadant et al. 2008). 
Specifically, ITGB4 has been reported to have an important role in cancer invasion 
and EMT (Masugi et al. 2015), possessing also features of cancer stem cell 
phenotype (Bieriea et al. 2017).  
Surgical pathology has traditionally been based on visual analysis of routine 
histological slides as well as immunohistochemical stainings. Along with 
increasing demands of standardization and to avoid interobserver variation, digital 
image analysis has received increasing interest. For several years automated image 
analysis has been possible in the evaluation of Ki-67-index as well as for estrogen 
and progesterone receptor stainings from cancer specimens (Tuominen et al. 2010). 
In addition, tumour-infiltrating lymphocytes and their subclasses have been 
analyzed for years with digital image analysis (Klauschen et al. 2018). Multiplex 
immunohistochemistry (multiplex IHC) makes it possible to study several 
biomarkers from one tissue section simultaneously, but the interpretation of these 
slides visually may be challenging and not provide reproducible results. For this 
purpose, whole-slide digital image analysis has shown promising accomplishments 
(Blom et al. 2017), and this method has been used in the original publication II for 
analyzing of TB associated EMT-markers. It is remarkable, that digitally analyzed 
ITGB4 -high bud count correlated better with survival outcome than visually 
analyzed tumour bud count from either H&E or CkPan stained TMA samples 
(Original publication II). However, the use of more complicated image analysis 
techniques may require standardization of equipment, software and configuration. 
For this reason it may take for some years, before more complicated image analysis 
techniques including deep learning based tissue analysis (Caie et al. 2016; Bychkov 
et al. 2018) can be applied more broadly in clinical pathology settings (Kratz et al. 
2019). 
6.3 CDX2 in relation to prognosis of stage II 
colorectal cancer (III) 
The caudal type homeobox 2 transcription factor (CDX2) is important for 
proliferation and differentiation of intestinal epithelial cells (Walters et al. 1997). 
During embryogenesis homeobox genes have a vital role for the development of 
embryo (Rawat et al. 2012). CDX2 has been observed to possess tumour 
suppressor function (Bakaris et al. 2008), and it affects Wnt/β-catenin signaling 
among others (Coskun et al. 2014). In addition, CDX2 expression has effect on 
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EMT by regulating the expression of claudin-1, which is an essential constituent of 
tight junctions (Bhat et al. 2012). Furthermore, CDX2 regulates the expression of 
EMT-associated proteins E-cadherin, vimentin and sialyl Lewis glycans a and x 
(Zhang et al. 2015; Sakuma et al. 2012). For this reason, it is no wonder, that 
inactivation of CDX2 contributes to colorectal tumorigenesis (Hryniuk et al. 2014). 
Decreased expression of CDX2 protein may be associated with gene promoter 
hypermethylation of this gene (Kameoka et al. 2015). Loss of CDX2-expression is 
associated with advanced tumour stage, poor differentiation, BRAF-mutation and 
MSI-H phenotype (Olsen et al. 2014, Sakamoto et al. 2017), and poor outcome 
(Baba et al. 2009; Dalerba et al. 2016; Lugli et al. 2008; Zhang et al. 2017). MSI-H 
and BRAF mutation correlate with CDX2 loss, which may suggest the association 
with serrated pathway in these tumours (Neumann et al. 2018). There are no 
previous reports concerning our observation of association between CDX2 loss and 
high ezrin protein expression. Both of these genes have an important role during 
embryonic development (Liu et al. 2018). Although both CDX2 loss and high ezrin 
protein expression correlate with poor prognosis in stage II colorectal cancer 
(Original publications I, III), further studies are needed concerning their possible 
combinatory synergistic effect. There are hardly any studies, which asses the 
prognostic significance of CDX2 specifically in stage II CRC only. In the current 
study we could show that loss of CDX2 to be an independent factor of poor 
outcome in stage II CRC, but only in patients with microsatellite stable phenotype. 
Also the study of Ryan et al. (2019) showed that poor prognosis associated with 
loss of CDX2 is limited to MSS patients, yet that study included CRC patients 
from several stages. The assessment of CDX2 protein expression in addition to 
MSI-status may identify high risk patients in need of adjuvant chemotherapy to 
exclude recurrent disease. However, the results must be confirmed in a prospective 
setting with a larger patient series. 
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7 Summary/Conclusions 
Treatment of stage II CRC is in dire need of new clinical biomarkers to identify 
high-risk patients better than before. The methods for this should be easy to apply 
them in all pathology laboratories. In this study, ezrin, CDX2 and TB-associated 
EMT markers have been tested for this purpose, and the following conclusions can 
be drawn:  
1) High ezrin protein expression together with microsatellite stable 
phenotype in tumours is an independent risk factor of poor DSS in stage 
II CRC patients.  
2) High ITGB4 budding count analyzed from TMAs with digital image 
analysis correlates with TB evaluated visually from H&E stained whole 
sections, and provides prognostic efficacy comparable to latter (HR = 
5.09 vs 7.55, Univariate Cox regression analysis for DSS), and it 
independently predicted poor DSS in two independent stage II CRC 
patient cohorts. In patients with high ITGB4 expression in their tumour 
buds, the localization of staining switched from the basal membrane to 
the cytoplasm.  
3) Loss of CDX2 protein expression together with microsatellite stable 
phenotype in tumours is an independent risk factor of poor DSS in stage 
II CRC patients.  
4) CDX2 loss correlates with other observed poor prognostic factors 
including high ezrin expression, EMT markers including low E-cadherin 
and tight junction disruption, suggesting both some functional 
relationship and possibility for some joint effects on the prognosis.  
Taken together, the results of these studies suggest, that especially stage II 
colorectal cancer patients with high ezrin expression and CDX2 loss combined 
with MSS phenotype in their tumours carry a risk of poor outcome. In addition, the 
biomarkers in the focus of the present study may have a potential to further 
improve the risk stratification of stage II colorectal cancer patients. However, 
further studies are needed to validate these findings. (Figure 7.).  
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Figure 7.  A suggested algorithm to identify high-risk stage II CRC patients. Grey box lists 
biomarkers identified in this study. 
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